GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Exscientia plc
Exscientia is a company using artificial intelligence to accelerate drug discovery. Its stock price is a venture bet that its platform will dramatically reduce the time and cost of drug development.
Share prices of companies in the market segment - AI
Exscientia is a British company that uses artificial intelligence to accelerate the discovery and development of new drugs. We've categorized it as "AI," and the chart below shows how investors view the use of AI in pharmaceuticals, one of the most promising fields.
Broad Market Index - GURU.Markets
Exscientia is a British biotech company that uses artificial intelligence to accelerate the discovery and development of new drugs. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Exscientia compares to it.
Change in the price of a company, segment, and market as a whole per day
EXAI - Daily change in the company's share price Exscientia plc
The daily price change of Exscientia plc, a company that uses AI to develop drugs, reflects the high volatility of the biotech and technology convergence. This metric measures the company's sensitivity to news about partnerships and research progress.
Daily change in the price of a set of shares in a market segment - AI
Exscientia uses artificial intelligence to accelerate drug discovery. This is a cutting-edge and highly speculative field at the intersection of biotech and AI. The chart below illustrates the high volatility typical of this sector, reflecting the enormous expectations and risks associated with Exscientia's technology.
Daily change in the price of a broad market stock, index - GURU.Markets
Exscientia is a British company using artificial intelligence to accelerate drug development. The company is located at the intersection of two hot sectors—AI and biotech. This creates high volatility, which contributes to overall market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Exscientia plc
Exscientia plc's year-over-year performance is a story about the application of AI in drug development. Its 12-month market cap is entirely dependent on progress in its clinical programs and partnerships with major pharmaceutical companies like Sanofi. The success of its AI platform could fundamentally accelerate and reduce the cost of developing new drugs.
Annual dynamics of market capitalization of the market segment - AI
Exscientia plc is a leading company using AI to accelerate drug discovery. Its technology platform is its key advantage. This chart shows how the market views its innovative yet capital-intensive approach to drug development compared to traditional biotech.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Exscientia, which uses AI to create drugs, is betting on a revolution in pharmaceuticals. Its performance relative to the market reflects investors' belief that its platform can significantly speed up and reduce the cost of drug development. Each new partnership is a powerful catalyst for growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Exscientia plc
Exscientia is a company using AI to accelerate drug discovery. Its monthly performance depends on progress in its own pipeline and its partnerships with major pharmaceutical companies. News about reaching research milestones is key.
Monthly dynamics of market capitalization of the market segment - AI
Exscientia uses artificial intelligence to accelerate the discovery and development of new drugs. This is one of the hottest topics in pharmaceuticals. The dynamics of the biotech sector reflect hopes that AI will make R&D cheaper and faster. Exscientia's story is an attempt to prove that its platform can truly revolutionize drug discovery.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Exscientia plc is a British company using artificial intelligence to accelerate the discovery and development of new drugs. Its business is betting on a revolution in pharmaceuticals. The broad market chart reflects its risk appetite, making it interesting to see how its partnerships with major pharmaceutical companies and progress in R&D have impacted its shares.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Exscientia plc
Exscientia plc uses artificial intelligence to accelerate drug development. Its weekly stock price is volatile, driven by news of partnerships with major pharmaceutical companies and progress in its own development programs.
Weekly dynamics of market capitalization of the market segment - AI
Exscientia uses artificial intelligence to accelerate drug discovery. This is one of the most promising areas at the intersection of AI and biotech. The chart will show whether Exscientia's share price fluctuations are driven by its unique partnerships and scientific breakthroughs or reflect the general hype surrounding AI in pharmaceuticals.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Exscientia uses AI to accelerate drug development, one of the most hyped topics in biotech. The company's shares are highly volatile, reflecting investors' faith in the AI revolution in medicine. The chart below will show this speculative dynamic.
Market capitalization of the company, segment and market as a whole
EXAI - Market capitalization of the company Exscientia plc
Exscientia's market capitalization reflects investors' bets on its platform, which uses artificial intelligence to accelerate drug discovery. Its volatile price reflects both the technology's enormous potential and the need to prove its effectiveness through successful clinical trials.
EXAI - Share of the company's market capitalization Exscientia plc within the market segment - AI
Exscientia uses artificial intelligence to accelerate drug discovery. Its market share as a service company in the vast pharmaceutical sector is still small. However, its market cap reflects investors' belief that its AI platform has the potential to revolutionize R&D and become an industry standard.
Market capitalization of the market segment - AI
Here's a chart showing the market capitalization of the biotech sector at the intersection of AI. Exscientia is a pioneer in using artificial intelligence to accelerate drug discovery. The explosive growth of this market you see reflects the hope that AI will revolutionize pharmaceuticals, and Exscientia is at the forefront of this movement.
Market capitalization of all companies included in a broad market index - GURU.Markets
Exscientia is a biotech company that uses artificial intelligence to accelerate the discovery and development of new drugs. Its market cap reflects a bet on AI in pharmaceuticals. The chart below shows the growing economic importance of this sector, which is transforming the approach to research.
Book value capitalization of the company, segment and market as a whole
EXAI - Book value capitalization of the company Exscientia plc
Exscientia's book value is determined by its unique platform, which uses artificial intelligence to accelerate the discovery and development of new drugs. The chart tells the story of a pioneer in AI drug discovery, investing its capital in creating a complex intangible asset capable of radically changing the pharmaceutical industry.
EXAI - Share of the company's book capitalization Exscientia plc within the market segment - AI
Exscientia uses AI to accelerate drug discovery. The chart shows its share of real R&D assets. These include its automated labs, where AI controls experiments, providing a unique resource for a new approach to pharmaceuticals.
Market segment balance sheet capitalization - AI
Exscientia uses artificial intelligence to accelerate the development of new drugs. Their value lies in their platform and data, not their manufacturing facilities. A book value chart will show their laboratory base, but it won't reflect the potential of their "lightweight" yet technologically sophisticated business model.
Book value of all companies included in the broad market index - GURU.Markets
Exscientia's assets are unique automated laboratories where artificial intelligence controls experiments to create new drugs. The chart shows how the company built this futuristic physics platform at the intersection of AI and biotechnology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Exscientia plc
Exscientia uses artificial intelligence to accelerate drug development. Its assets are its AI platform and data, not traditional laboratories. Its schedule is a clear bet on revolutionizing pharmaceuticals. Its market valuation reflects its belief in the potential of its technology to transform the industry.
Market to book capitalization ratio in a market segment - AI
Exscientia uses artificial intelligence to significantly accelerate the discovery and development of new drugs. Its value lies in its advanced platform and partnerships with major pharmaceutical companies. The chart shows a significant premium in market capitalization over its assets, reflecting investor confidence in the AI revolution in pharmaceuticals.
Market to book capitalization ratio for the market as a whole
Exscientia uses AI to accelerate drug development. Like other pharma tech companies, its value lies in its platform and the potential for future discoveries. This chart shows the vast gap between its market valuation, based on faith in its technology, and its modest tangible assets.
Debts of the company, segment and market as a whole
EXAI - Company debts Exscientia plc
Exscientia uses artificial intelligence to accelerate the discovery and development of new drugs. This chart shows the company's financial model at the intersection of AI and biotech. It has raised significant capital from investors and pharmaceutical partners to fund its innovative, yet capital-intensive, platform.
Market segment debts - AI
Exscientia uses artificial intelligence to accelerate drug discovery, one of the most advanced fields at the intersection of biotechnology and IT. This chart illustrates the company's financial model, which is betting its AI platform will revolutionize pharmaceuticals.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Exscientia plc
Exscientia uses artificial intelligence to accelerate drug development. This chart shows the tech company's financial structure. Debt at a stage when its platform doesn't yet generate stable revenue from partnerships is a high-risk factor that limits flexibility.
Market segment debt to market segment book capitalization - AI
Exscientia uses artificial intelligence to accelerate the discovery and development of new drugs. This chart shows the debt load in the AI and biotech sector. It is an indicator of the company's ability to finance its capital-intensive platform, which has the potential to revolutionize the pharmaceutical industry.
Debt to book value of all companies in the market
Exscientia uses artificial intelligence to accelerate the discovery and development of new drugs. This is a cutting-edge, yet capital-intensive, field. This chart of total market debt shows how willing investors and lenders are to finance companies with revolutionary, but not yet commercially proven, business models.
P/E of the company, segment and market as a whole
P/E - Exscientia plc
Exscientia is a pharmaceutical company using artificial intelligence to accelerate the discovery and development of new drugs. This chart reflects investor confidence in an AI-driven revolution in R&D. Its performance is speculative and depends on the success of its platform and partnerships with major pharma companies.
P/E of the market segment - AI
Exscientia is a pharmaceutical company that uses artificial intelligence (AI) to accelerate the discovery and development of new drugs. Their platform enables faster identification of promising molecules. This chart shows the average valuation for the AI sector, reflecting investor expectations that AI will revolutionize drug discovery.
P/E of the market as a whole
Exscientia is a company that uses artificial intelligence to accelerate the discovery and development of new drugs. Its valuation is a pure bet on its technology platform and is not tied to the general economic cycles reflected in this chart. Its fate is decided in the lab and depends on its ability to prove the effectiveness of its approach.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Exscientia plc
Exscientia is a British company using artificial intelligence to accelerate the discovery and development of new drugs. This chart reflects investors' confidence in its revolutionary platform. Future profits depend on the success of its internal programs and partnerships with major pharmaceutical companies.
%20P%2FE%20Exscientia%20plc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Exscientia-plc&v=1772560568459 "Chart of the company's future (projected) P/E Exscientia plc")
Future (projected) P/E of the market segment - AI
Exscientia is a pharmaceutical company using artificial intelligence (AI) to accelerate the discovery and development of new drugs. This chart shows general expectations for the biotech sector. EXAI's position relative to the average reflects whether investors believe their AI platform can truly revolutionize pharmaceutical research.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20AI&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-AI&v=1772560568470 "Future (projected) P/E graph of the market segment - AI")
Future (projected) P/E of the market as a whole
Exscientia plc is a British company that uses artificial intelligence to accelerate the discovery and development of new drugs. Its platform analyzes massive amounts of data to create new molecules. This chart of overall market expectations shows how willing investors are to invest in breakthrough technology platforms that could transform the pharmaceutical industry.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772560568473 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Exscientia plc
Exscientia is a pharmaceutical company that uses artificial intelligence (AI) to accelerate the discovery and development of new drugs. Its financials reflect significant investments in its AI platform and partnerships with major pharmaceutical companies. Future profits depend on the success of this innovative approach.
Profit of companies in the market segment - AI
Exscientia uses artificial intelligence (AI) to accelerate the discovery and development of new drugs. The company partners with major pharmaceutical companies. This chart shows the overall profitability of the AI sector. It illustrates how successfully advanced AI technologies are being applied in one of the most complex and capital-intensive industries—pharmaceuticals.
Overall market profit
Exscientia uses artificial intelligence (AI) to accelerate drug discovery. This is a cutting-edge field that requires significant investment. The company's success depends on the effectiveness of its AI platform and partnerships with pharmaceutical companies. The positive economic backdrop, visible in this chart, facilitates raising capital for the development of such innovative technologies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Exscientia plc
Exscientia is a company using artificial intelligence (AI) to accelerate the discovery and development of new drugs. Future profits depend on the success of its platform and partnerships with pharmaceutical companies. This chart reflects analysts' speculative expectations regarding the potential of AI to revolutionize pharmaceutical R&D.
%20profit%20of%20the%20company%20Exscientia%20plc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Exscientia-plc&v=1772560568602 "Graph of future (projected) profit of the company Exscientia plc")
Future (predicted) profit of companies in the market segment - AI
Exscientia uses artificial intelligence to accelerate the discovery and development of new drugs. The company's technology enables the analysis of massive data sets to identify promising molecules. This graph shows forecasts for the entire biotech sector, helping to assess how Exscientia's revolutionary approach could change the pharmaceutical industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20AI&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-AI&v=1772560568616 "Graph of future (predicted) profits of companies in a market segment - AI")
Future (predicted) profit of the market as a whole
Exscientia uses artificial intelligence to accelerate drug development. As a tech company at the intersection of biotech and pharmaceuticals, its success depends on the effectiveness of its platform and partnerships with pharmaceutical companies. The overall economic situation, reflected in the graph, influences the R&D budgets of its potential clients.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772560568674 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Exscientia plc
Exscientia uses artificial intelligence to accelerate drug discovery. With minimal current revenue, its massive valuation, visible in this chart, is a bet on the revolutionary potential of its platform. This valuation reflects investors' belief that AI will fundamentally transform the pharmaceutical industry.
P/S market segment - AI
Exscientia uses artificial intelligence (AI) to accelerate the discovery and development of new drugs. Future revenue depends on the success of its platform and partnerships. This chart for the AI and biotech sector reflects investor expectations for Exscientia's potential to revolutionize the pharmaceutical industry using AI.
P/S of the market as a whole
Exscientia is a pharmaceutical company that uses artificial intelligence (AI) to accelerate the discovery and development of new drugs. This market valuation chart helps us understand the significant premium investors are willing to pay for this cutting-edge technology platform, which has the potential to revolutionize the pharmaceutical industry.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Exscientia plc
Exscientia is a company at the intersection of artificial intelligence (AI) and drug discovery. It uses its AI platform to accelerate the discovery and development of new molecules to treat diseases. This chart shows how the market is pricing in future revenue from partnerships and licensing agreements, betting on the effectiveness of its technology platform.
%20P%2FS%20Exscientia%20plc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Exscientia-plc&v=1772560568788 "The graph of the company's future (projected) P/S Exscientia plc")
Future (projected) P/S of the market segment - AI
Exscientia uses artificial intelligence to accelerate the discovery and development of new drugs. The company's high valuation reflects investors' confidence in its ability to make pharmaceutical R&D faster and more cost-effective, potentially leading to the development of breakthrough drugs in partnership with major pharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20AI&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-AI&v=1772560568875 "Future (projected) P/S market segment graph - AI")
Future (projected) P/S of the market as a whole
Exscientia plc uses artificial intelligence to accelerate the drug discovery process. The company is at the forefront of the biotech revolution. The future revenue growth expectations reflected here are largely based on the breakthroughs enabled by the Exscientia platform.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772560568897 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Exscientia plc
Exscientia uses artificial intelligence (AI) to accelerate the discovery and development of new drugs. This chart shows revenue generated through upfront fees, milestone payments, and royalties from partnerships with major pharmaceutical companies.
Sales of companies in the market segment - AI
Exscientia (EXAI) is a pharmaceutical company that uses artificial intelligence to accelerate the discovery and development of new drugs. Its platform enables faster identification of promising molecules. This chart shows revenue in the AI sector. Exscientia is at the forefront of the R&D revolution, striving to make drug development more efficient and cost-effective.
Overall market sales
Exscientia uses artificial intelligence (AI) to accelerate the discovery and development of new drugs. Its success depends on the effectiveness of its platform and partnerships with pharmaceutical companies. This trend in overall economic activity influences R&D investment. Market growth allows pharmaceutical companies to invest more in innovative approaches, such as AI-based drug discovery.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Exscientia plc
Exscientia is a company that uses artificial intelligence to accelerate the discovery and development of new drugs. Its revenue depends on partnerships with major pharmaceutical companies and the success of its internal programs. This chart reflects analyst forecasts, which are essentially a bet on the effectiveness of its AI platform and the commercial potential of the drugs it develops.
%20sales%20of%20the%20company%20Exscientia%20plc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Exscientia-plc&v=1772560569106 "Schedule of future (projected) sales of the company Exscientia plc")
Future (projected) sales of companies in the market segment - AI
Exscientia uses artificial intelligence to accelerate the discovery and development of new drugs. This forecast chart shows potential future revenue from partnerships with pharmaceutical companies and from its own developments. This is the analysts' view on the commercialization of their advanced AI platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20AI&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-AI&v=1772560569163 "Schedule of future (projected) sales of companies in the market segment - AI")
Future (projected) sales of the market as a whole
Exscientia plc uses artificial intelligence to accelerate the discovery and development of new drugs. Its platform analyzes massive data sets to identify promising molecules. This chart illustrates the overall investment climate, and Exscientia's partnerships with major pharmaceutical companies are an indicator of how AI is transforming the pharmaceutical industry.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772560569165 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Exscientia plc
Exscientia uses artificial intelligence to accelerate the discovery and development of new drugs. The company's profitability depends on the success of its AI platform and partnerships with major pharmaceutical companies. The chart shows the company's financial position at a stage when it is actively investing in technologies that have the potential to revolutionize the pharmaceutical industry.
Market segment marginality - AI
Exscientia is a company using artificial intelligence to accelerate the discovery and development of new drugs. This chart reflects its operating expenses during the research phase. Future profitability depends on the success of its AI platform in creating effective drugs and securing partnerships with major pharmaceutical companies.
Market marginality as a whole
Exscientia uses artificial intelligence to accelerate the discovery and development of new drugs. The company is at the forefront of the convergence of technology and pharmaceuticals. This gross profitability chart reflects the market's willingness to fund such breakthrough, yet capital-intensive, projects. Economic growth is driving investment in innovative platforms like Exscientia.
Employees in the company, segment and market as a whole
Number of employees in the company Exscientia plc
Exscientia uses artificial intelligence (AI) to accelerate the discovery and development of new drugs, revolutionizing pharmaceuticals. This graphic shows an interdisciplinary team of biologists, chemists, and AI specialists working together to create the "pharmacy of the future."
Share of the company's employees Exscientia plc within the market segment - AI
Exscientia uses artificial intelligence to accelerate drug discovery. Its staff, working in this cutting-edge field, is a unique combination of biological scientists and machine learning specialists. This chart shows the company's investment in human and computational intelligence to revolutionize pharmaceutical research.
Number of employees in the market segment - AI
Exscientia plc uses artificial intelligence to accelerate the discovery and development of new drugs. This chart, which charts employment in the AI sector, demonstrates how this technology is transforming the pharmaceutical industry. For Exscientia, the growing number of AI and bioinformatics specialists indicates recognition of their approach and an increase in partnerships with major pharmaceutical companies.
Number of employees in the market as a whole
Exscientia uses artificial intelligence (AI) to accelerate the discovery and development of new drugs. This is at the cutting edge of pharmaceuticals. The growth in overall employment, reflected in this chart, indicates a healthy economy capable of funding long-term, capital-intensive innovation. A strong economy attracts investment in breakthrough technology platforms like Exscientia's.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Exscientia plc (EXAI)
Exscientia (EXAI) uses artificial intelligence to accelerate drug discovery. It's a synergy between biotech and AI. This chart shows an extremely high valuation of intellectual capital. The market values their AI platform as potentially replacing thousands of hours of lab work, resulting in a huge market value per employee.
%20of%20the%20company%20Exscientia%20plc%20(EXAI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Exscientia-plc-EXAI&v=1772560569577 "Chart of market capitalization per employee (in thousands of dollars) of the company Exscientia plc (EXAI)")
Market capitalization per employee (in thousands of dollars) in the market segment - AI
Exscientia uses artificial intelligence to accelerate the drug discovery process. In this cutting-edge field, its market cap reflects the potential of its revolutionary technology. This metric demonstrates the enormous future value investors are placing on its AI platform per employee.
%20by%20market%20segment%20-%20AI&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-AI&v=1772560569647 "Market capitalization per employee (in thousands of dollars) by market segment - AI")
Market capitalization per employee (in thousands of dollars) for the overall market
Exscientia is a company using artificial intelligence to accelerate drug discovery. It is at the forefront of the convergence of biotech and AI. This chart for Exscientia illustrates how technology platforms capable of revolutionizing entire industries can have astronomical market capitalization per employee, reflecting their enormous potential.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772560569818 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Exscientia plc (EXAI)
Exscientia uses AI to accelerate drug discovery. It's a "next-generation" biotech company. Like other R&D companies, it's not profitable. This graph shows a negative net loss per employee. But their main argument is that, thanks to AI, this "loss" per scientist is much more effective and productive than in traditional pharma.
%20Chart%20Exscientia%20plc%20(EXAI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Exscientia-plc-EXAI&v=1772560569943 "Company Profit Per Employee (in thousands of dollars) Chart Exscientia plc (EXAI)")
Profit per employee (in thousands of dollars) in the market segment - AI
Exscientia uses artificial intelligence to accelerate the discovery and development of new drugs. In AI-driven drug discovery, the efficiency of algorithms and a small team of scientists is key. This metric demonstrates the value each employee creates, reflecting the company's potential to revolutionize the pharmaceutical industry.
%20in%20the%20market%20segment%20-%20AI&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-AI&v=1772560570119 "Chart of profit per employee (in thousands of dollars) in the market segment - AI")
Profit per employee (in thousands of dollars) for the market as a whole
Exscientia is a company using artificial intelligence (AI) to accelerate the discovery and development of new drugs. It is an R&D platform at the intersection of biotech and AI. This graph shows the average profitability of one employee in the economy. It provides investors with context: the AI-biotech sector strives for exponential returns on personnel by automating R&D.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772560570176 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Exscientia plc (EXAI)
Exscientia uses artificial intelligence to accelerate the discovery and development of new drugs. As a company at the intersection of biotech and AI, its revenue per employee comes from partnerships with pharmaceutical giants. The chart shows how its technology platform generates revenue from upfront and milestone payments, helping create the drugs of the future.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Exscientia-plc-EXAI&v=1772560570184 "Sales chart per company employee Exscientia plc (EXAI)")
Sales per employee in the market segment - AI
Exscientia (EXAI) is a pharmaceutical company using artificial intelligence (AI) to accelerate the discovery and development of new drugs. This chart shows the average revenue per employee in the segment. It helps assess how effectively Exscientia is using its AI platform and staff to generate revenue (from partnerships).
Sales per employee for the market as a whole
Exscientia (EXAI) is a biotech company that uses artificial intelligence (AI) to accelerate the discovery and development of new drugs. It is an R&D platform. This metric reflects the revenue (in the form of milestone payments from pharmaceutical partners) generated by their AI platform and research team per employee, in anticipation of future royalties.
Short shares by company, segment and market as a whole
Shares shorted by company Exscientia plc (EXAI)
Exscientia (EXAI) is a British company using AI to accelerate drug discovery. This is a highly speculative area. This chart shows short interest. The high bearish bets reflect not only the risks (will AI prove effective?) but also the recent scandal involving the CEO's dismissal due to inappropriate relationships, which has undermined investor confidence. (348)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Exscientia-plc-EXAI&v=1772560570331 "Short Shares Chart for the Company Exscientia plc (EXAI)")
Shares shorted by market segment - AI
Exscientia (EXAI) uses artificial intelligence to accelerate the discovery and development of new drugs. The chart below shows the overall short position in the "AI in biotech" sector. It illustrates how skeptical investors are about the true effectiveness of AI in R&D or believe the sector's valuations are overvalued.
Shares shorted by the overall market
Exscientia uses AI to accelerate drug development. It's a futuristic technology that requires massive R&D budgets. This chart measures overall fear. When investors are afraid, their planning horizon shrinks to days. They sell off speculative, pre-profit biotechs like EXAI en masse, fearing they'll run out of money in a risk-off environment.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Exscientia plc (EXAI)
Exscientia is one of the hottest companies using AI to accelerate drug discovery. It's betting on the platform, not a specific drug. This indicator measures the fever of AI hype. It overheats on news of partnerships with Big Pharma and cools down in anticipation of real results.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Exscientia-plc-EXAI&v=1772560570459 "RSI 14 indicator chart for the company's stock Exscientia plc (EXAI)")
RSI 14 Market Segment - AI
Exscientia plc is a biotech company that uses artificial intelligence to accelerate the discovery and development of new drugs. This is "AI-driven" R&D. This chart shows the overall "temperature" in the AI sector applied to biotech. It helps us understand whether EXscientia's growth is part of the general hype surrounding AI or the result of its clinical successes.
RSI 14 for the overall market
Exscientia (EXAI) uses AI to discover drugs. This chart is an indicator of hype and capital availability. In the euphoria, investors are ready to fund the "future" (AI + biotech). In a panic, they flee unprofitable R&D projects, and the cash spigot for Exscientia, which is burning through hundreds of millions, could be shut off.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast EXAI (Exscientia plc)
Exscientia is a UK-based TechBio company that uses its AI to radically accelerate the discovery and design of new drugs. This chart shows the speculative average price target from analysts, based on their belief in this R&D platform and its ability to partner with big pharma.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-EXAI-Exscientia-plc&v=1772560570577 "A chart showing analyst consensus forecasts for the expected stock price. EXAI (Exscientia plc)")
The difference between the consensus estimate and the actual stock price EXAI (Exscientia plc)
Exscientia is an "AI drug hunter." The British company uses its AI platform to *accelerate* R&D, discovering new molecules for cancer treatment. This chart shows how far the current share price deviates from its "fair" value. It reflects analysts' belief that their AI platform can truly be a game-changer for the pharmaceutical industry.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-EXAI-Exscientia-plc&v=1772560570629 "A chart showing the difference between the consensus forecast and the actual stock price. EXAI (Exscientia plc)")
Analyst consensus forecast for stock prices by market segment - AI
Exscientia is a TechBio company using AI platforms to radically accelerate drug discovery (R&D). This chart shows analysts' overall expectations across the AI sector. It reflects whether experts believe AI can truly disrupt the traditional drug development model.
Analysts' consensus forecast for the overall market share price
Exscientia is a biotech company that uses AI to "automate" the drug discovery process, aiming to make it faster and cheaper. This chart shows the overall "risk appetite" in the market. For Exscientia, which operates at the intersection of AI and biotech, overall optimism (risk appetite) is critical to funding their high-tech research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Exscientia plc
Exscientia is an AI brain for drug R&D. It's not a biotech, but an AI company that uses its computing platform to design and discover new molecules (drugs) faster and cheaper than traditional pharma. This chart is a summary indicator of their platform rate. It reflects not sales, but (critically important) payments from their R&D partners (Sanofi, BMS) and faith in their AI approach.
AKIMA Market Segment Index - AI
Exscientia is a biotech company that uses AI for drug discovery. Their platform analyzes massive data sets to discover new candidate molecules much faster than humans. It's AI pharma. This chart compares their composite index to the sector, showing how far their AI approach outpaces traditional R&D.
The AKIM Index for the overall market
Exscientia is a pharma company using AI to discover and develop new drugs. This chart, which reflects the market average, is a backdrop. It helps assess how this story of the confluence of technology and biology (with Recursion) fits into the context of overall macroeconomic trends.
